Tegafur substitution for 5-Fu in combination with actinomycin D to treat gestational trophoblastic neoplasm

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Peng, Mei ^a   Ding, Yiling ^a   Yu, Ling ^a   Deng, Yali ^a   Lai, Weisi ^a   Hu, Yun ^a   Zhang, Hongwen ^a   Wu, Xianqing ^a   Fan, Hong ^a   Ding, Hui ^a   Wu, Yilin ^a   Tao, Guangshi ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; DACTINOMYCIN; FLUOROURACIL; TEGAFUR; ANTINEOPLASTIC AGENT;

ADULT; ADVERSE OUTCOME; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DENTAL ULCER; DIARRHEA; DRUG EFFECT; FEMALE; FEVER; FOLLOW UP; HUMAN; INCIDENCE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PHLEBITIS; RECURRENCE RISK; SKIN DEFECT; TOOTH DISEASE; TREATMENT RESPONSE; TROPHOBLASTIC TUMOR; CHEMISTRY; GESTATIONAL TROPHOBLASTIC DISEASE; PREGNANCY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACTINOMYCIN; FEMALE; FLUOROURACIL; GESTATIONAL TROPHOBLASTIC DISEASE; HUMANS; PREGNANCY; TEGAFUR;

EID: 84957916487     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143531     Document Type: Article

References (35)

1. Feng YJ, Shen K. Obstetrics and gynecology (for 8-year programme course). 2nded. Beijing: People's Medical Publishing House; 2010.
2. Shi YF. Hydatid mole, choriocarcinoma and the associated diseases. Beijing: People's Medical Publishing House; 2006.
3. Shi YF, He M. The comparison of malignant change of hydatidiform mole in two groups before and after twenty years. Chinese Journal of Clinical Obstetric and Gynecology. 2000;1:29-31.
4. Goldstein DP, Berkowitz RS. Current management of gestational trophoblastic neoplasia. Hematol Oncol Clin North Am. 2012;26:111-131. doi: 10.1016/j.hoc.2011.10.007 PMID: 22244665
5. Ngan S, Seckl MJ. Gestational trophoblastic neoplasia management: an update. CurrOpin Oncol. 2007;19:486-491. PMID: 17762576
6. Li MC, Hertz R, Spencer DB. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. ProcSoc Exp Biol Med. 1956;93:361-366. PMID: 13379512
7. Li MC. Trophoblastic disease: natural history, diagnosis, and treatment. Ann Intern Med. 1971;74:102-112. PMID: 4321708
8. Song HZ, Yang XY, Xiang Y. Diagnosis and treatment of trophoblastic neoplasm. Beijing: People's Medical Publishing House; 2004.
9. Berkowitz RS, Goldstein DP. Gestational trophoblastic disease. In: Berek JS, editor. Novak's Gynecology (13th Ed.). Philadelphia: Lippincott Williams &Wilkins 2002. pp. 1353-1373.
10. Chalouhi GE, Golfier F, Soignon P, Massardier J, Guastalla JP, Trillet-Lenoir V, et al. Methotrexate for 2000 FIGO low-risk gestational trophblastic neoplasia patients: efficacy and toxicity. AM J Obstet Gynecol. 2009:643-646.
11. Ngan S, Seckl MJ. Gestational trophoblastic neoplasia management: an update. CurrOpin Oncol. 2007;19:486-491. PMID: 17762576
12. Rodrignez N, Goldstein DP, Berkowitz RS. Treating gestational trophoblastic disease. Expert Opin Plarmacother. 2010;11:3027-3039.
13. Wang SL, Zhang CS, Peng HQ, Wu KH. Treatment of malignant trophoblastic tumors. An analysis of 209 cases. Chin Med J (Engl). 1991;104:156-160.
14. Zhou X, Chen Y, Li Y, Duan Z. Partial hydatidiform mole progression into invasive mole with lung metastasis following in vitro fertilization. Oncol Lett. 2012;3:659-661. PMID: 22740971
15. Manopunya M, Suprasert P. Resistant gestational trophoblastic neoplasia patients treated with 5-fluorouracil plus actinomycin D. Asian Pac J Cancer Prev. 2012;13:387-390. PMID: 22502707
16. Wang CM, Dixon PH, Decordova S, Hodges MD, Sebire NJ, Ozalp S, et al. Identification of 13 novel NLRP7 mutations in 20 families with recurrent hydatidiform mole; missense mutations cluster in the leucine-rich region. J Med Genet. 2009;46:569-575. doi: 10.1136/jmg.2008.064196 PMID: 19246479
17. Zhou JC. Practical tumor internal medicine. Beijing: People's Medical Publishing House; 2003.
18. Tsuburaya A, Yoshida K, Kobayashi M, Yoshino S, Takahashi M, Takiguchi N, et al. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol. 2014;15:886-893. doi: 10.1016/S1470-2045 (14) 70025-7 PMID: 24954805
19. Takayama K, Kawasaki M, Ninomiya K, Motohiro A, Fujita M, Watanabe K, et al. Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer. Respirology. 2008;13:103-107. doi: 10.1111/j.1440-1843.2007.01190.x PMID: 18197918
20. Cao J. Comparison of therapeutic effect between Tegafur and 5-Fu in treatment of non-small cell lung cancer, World Pharmaceutical Newslette. 2007:38-39.
21. Wang FM, Sun J, Zhu L. Observation of the efficacy of radio-chemotherapy for 113 cases advanced T-stage nasopharyngel carcinoma. The Practical Journal of Cancer 2007:77-80.
22. Soper JT, Mutch DG, Schink JC. Diagnosis and treatment of gestational trophoblastic disease: ACOG practice Bulletin NO. 53. Gynecol Oncol. 2004;93:575-585. PMID: 15196847
23. FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. Inter J Gynecol Obstet. 2002;77:285-287.
24. WHO. WHO handbook for reporting results of cancer treatment WHO offset publication No. 48. Geneva (Switzerland): World Health Organization; 1979.
25. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancertreatment. Cancer. 1981;47:207-214. PMID: 7459811
26. Wan XR, Yang XY. Chemotherapy of malignant trophoblastic neoplasm. Chinese Journal of Practical Gynecology and Obstetrics. 2002;17:398-400.
27. Eirksson L., Wells T, Steed H, Schepansky A, Capstick V, Hoskins P, et al. Combined methoterxatedactionomycin: an effective therapy for low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2012;124:553-557. doi: 10.1016/j.ygyno. 2011.10.036 PMID: 22079360
28. Komatsu T, Yamazaki H, Shimada N, Nagayama S, Kawaguchi Y, Nakajima M, et al. Involvement of microsomal cytochrome P450 and cytosolic thymidine phospho-rylase in 5-fluorouracil formation from tegafur in human liver. Clin Cancer Res. 2001;7:675-681. PMID: 11297264
29. Sun Y. Oncology in internal medicine. Beijing: People's Medical Publishing House; 2001. pp. 523-548.
30. Zhou JC. The clinical application of anti-tumor drugs. Beijing: Chemical Industry Press;
31. Chen XQ, Jin YY. New pharmacology. Beijing: People's Medical Publishing House; 2003. pp. 673-674.
32. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist. 2002;7:288-323. PMID: 12185293
33. Ajani JA, Lee FC, Singh DA, Haller DG, Lenz HJ, Benson AB, et al. Mulicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2005;24:663-667.
34. Li ZY, Zhang Q, Yang JS, Ning SQ, Yi TN. Effects of nedaplatin plus futraful chemotherapy in the treatment of advanced esophageal carcinoma; Chinese Clinical Oncology. 2009;114:1022-1023.
35. Zhao YF, Shen B, Song XY. Short-term effects of nedaplatin plus tegafur chemotherapy in the treatment of advanced esophageal carcinoma. Chinese Clinical Oncology. 2007;12:699-700 (in Chinese).